RARECast

A podcast by RARECast - Thursdays

Thursdays

Categories:

512 Episodes

  1. Mapping Spheres of Influence

    Published: 1/4/2024
  2. Bringing Precision to the Treatment of Rare Cancers

    Published: 12/28/2023
  3. The Challenges of Developing a Therapy for Pregnant Women with A Rare Condition

    Published: 12/21/2023
  4. How One Drug Developer Is Addressing Health Inequities

    Published: 12/14/2023
  5. Accelerating the Development of Genetic Medicines with AI

    Published: 12/7/2023
  6. Leveraging AI to Address the Neuropsychiatric Conditions Associated with a Rare Disease

    Published: 11/30/2023
  7. In Pursuit of a Treatment for His Son, A Lawyer Becomes a Biotech Executive

    Published: 11/22/2023
  8. In Push for Treatment, a Patient Organization Becomes a Trial Sponsor

    Published: 11/16/2023
  9. Delayed Diagnosis of Rare Diseases Takes Staggering Economic Toll

    Published: 11/9/2023
  10. A Cell Therapy to Control Heart-Damaging Inflammation in Duchenne

    Published: 11/2/2023
  11. Stimulating the Growth of Muscle Mass in People with Neuromuscular Diseases

    Published: 10/26/2023
  12. Turning Grief into Action

    Published: 10/19/2023
  13. A Plea to the FDA to Give an Ultra-Rare Disease Drug a Fair Hearing

    Published: 10/12/2023
  14. How the Woolly Mammoth Beat a Path to Better Gene Therapies

    Published: 10/5/2023
  15. A Genetic Counselor’s Journey into Patient Advocacy

    Published: 9/28/2023
  16. A Company in the Fold of Rare Disease

    Published: 9/21/2023
  17. Disabling Antibodies that Drive Rare, Immunological Conditions

    Published: 9/14/2023
  18. Keeping the Sentinels of the Brain Vigilant

    Published: 9/7/2023
  19. Considering the Unfinished Work in Cystic Fibrosis

    Published: 8/31/2023
  20. How to Advocate for Yourself as You Battle Cancer

    Published: 8/24/2023

3 / 26

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.